Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience.

Dijana PerkovićPetrić MarinIvona BožićKatarina BorićDaniela Marasović KrstulovićMislav RadićDušanka Martinović Kaliterna

Published in: Wiener klinische Wochenschrift (2020)

The results of the study suggest that IVIG may be an additional treatment option together with CYC for patients for whom other therapies have failed, but further studies on the exact role of IVIG in the treatment of severe SSc are required.

Keyphrases

systemic sclerosis
low dose
high dose
interstitial lung disease
ejection fraction
newly diagnosed
prognostic factors
early onset
rheumatoid arthritis
replacement therapy
patient reported outcomes
molecular dynamics
case control